title: Radiotherapy-induced nausea and vomiting.
abstract: Radiotherapy-induced nausea and vomiting (RINV) are common and troublesome symptoms experienced by patients undergoing radiotherapy. Although quality of life and symptom control now figure prominently in evaluations of cancer therapies, progress in RINV research and clinical prevention has been slow. This article summarizes the major guidelines for the prevention of RINV; their structure, recommendations, evidence base and notable issues. It also examines the current challenges and controversies related to RINV clinical management and research, and provides possible solutions for them that could ultimately lead to better patient care.
authors.affiliation: Radiation Oncology and Pharmacy Departments, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada.
authors.forename: Kristopher
authors.initials: K
authors.lastname: Dennis
authors.forename: Ernesto
authors.initials: E
authors.lastname: Maranzano
authors.forename: Carlo
authors.initials: C
authors.lastname: De Angelis
authors.forename: Lori
authors.initials: L
authors.lastname: Holden
authors.forename: Shun
authors.initials: S
authors.lastname: Wong
authors.forename: Edward
authors.initials: E
authors.lastname: Chow
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D009369:Neoplasms / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000932:Antiemetics